Background: Despite its potentially significant impact on disease outcome, peripheral nervous system involvement in systemic lupus erythematosus has received little attention. Objective: The objective of this study was to assess the prevalence and clinical features of peripheral nervous system involvement in a large cohort of systemic lupus erythematosus patients. Methods: The records of systemic lupus erythematosus patients examined at two tertiary referral centres over a period of 14 years (from 2000 to 2014) were analyzed. Peripheral nervous system events were ascertained according to the 1999 American College of Rheumatology case definitions and by using an attribution algorithm for neuropsychiatric events. Prevalence of peripheral nervous system in systemic lupus erythematosus and demographic, clinical and laboratory features were assessed. Patients with peripheral nervous system events were compared with a control group of systemic lupus erythematosus patients without peripheral nervous system involvement. Results: In a retrospective cohort of 1224 patients, the overall prevalence of peripheral nervous system involvement was 6.9% (85 patients, 95% confidence interval 0.06-0.08), with 68% of peripheral nervous system events attributable to systemic lupus erythematosus. Polyneuropathy was the most common manifestation observed (38 events, 39.2%), followed by cranial neuropathy in 30 cases (30.9%) and 12 cases of single (12.4%) or multiple (eight events, 8.2%) mononeuritis. The average age of systemic lupus erythematosus onset was significantly higher in patients with peripheral nervous system events than in controls (mean AE standard deviation: 45.9 AE 14.8 vs. 37.1 AE 14.0) and they were more likely to have higher SLEDAI-2K and SLICC/ACR Damage Index scores, as well as hypertension and livedo reticularis. A subgroup analysis of events deemed to be systemic lupus erythematosus-related provided similar results. Conclusion: Peripheral nervous system manifestations are a potential complication of systemic lupus erythematosus. Careful neurological assessment should therefore be included in the diagnostic workup of patients with systemic lupus erythematosus, especially in those with later onset and greater damage and disease activity. Lupus (2019) 28, 465-474.
Introduction
Systemic lupus erythematosus (SLE) is an immunemediated disease characterized by the production of autoantibodies and the deposition of immunecomplexes which can affect multiple organs and systems, including both the central (CNS) and peripheral nervous systems (PNS). The prevalence of neuropsychiatric lupus (NPSLE) varies widely from study to study, depending on the type of manifestations and inclusion criteria considered, and the lack of standardized evaluation measures. 1 In 1999, the American College of Rheumatology (ACR) provided the definitions for seven peripheral and 12 central clinical neuropsychiatric (NP) manifestations associated with SLE. 2 However, to date, little is known about the actual prevalence of PNS involvement in SLE (PNSLE) or the demographic and specific immunological factors associated with this type of involvement. 2 Indeed, most of the studies evaluating NP involvement in SLE and applying the 1999 ACR nomenclature have typically been retrospective cohort studies considering both peripheral and central involvement. Nonetheless, they reported a prevalence of PNS complications ranging between 2 and 10%, and a higher predominance of polyneuropathy (2-3%) and mononeuritis (single or multiple: 0.5-1%) than rare or unusual events such as acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barre´syndrome (GBS), 0.1%), myasthenia gravis (0.1%) and plexopathy (<0.1%). [3] [4] [5] [6] According to some authors, the 1999 ACR classification should be reassessed to include, for instance, small-fibre neuropathy among the peripheral syndromes occurring in PNSLE. [7] [8] [9] Indeed, the diagnosis of PNSLE remains a relevant clinical challenge, as up to one third of peripheral neuropathies (PN) are recognized as having a non-SLE aetiology, 7 with potential alternative causes being entrapment neuropathies, diabetes and infectious, endocrine, metabolic, critical, genetic, nutritional, traumatic, neoplastic and iatrogenic disorders. 10 Hence the present study aimed to determine the prevalence of PNS involvement in a large cohort of patients with SLE from two tertiary referral centres, distinguishing between the events attributed to SLE and non-SLE causes. The secondary objective was to profile PNS involvement in SLE by analyzing patients' clinical and serological characteristics, in addition to specific and non-specific risk factors, treatment approaches and short-term outcomes.
Methods

Participants
We retrospectively analyzed the medical records pertaining to patients with SLE, examined over a 14-year period between 1 January 2000 and 31 December 2014 at two tertiary referral centres for SLE, namely the Ferrara University Hospital and Cagliari University Clinic Rheumatology Units. For inclusion, SLE diagnosis had to be made according to the 1997 ACR revised classification criteria. 11 Signs and/or symptoms of PNS involvement were identified from the clinical and laboratory information in the available documentation (clinical hospital records, patient charts and the clinics' lupus database), and only patients with a clinical follow-up of at least one year were included in the study. As a control group, patients examined during the same period and suffering from SLE but without NP abnormalities, matched for sex and disease duration, were randomly retrieved from the clinics' lupus database, using an alphabetical list (1:3 ratio). The study was approved by the local Ethics Committees of the participating centres; all participants gave informed consent for their data to be included.
Case assessment
Each case of PNS involvement was further characterized at the time of neurological diagnosis. For each PNS event, we evaluated the disease duration from the diagnosis of SLE to the time of neurological diagnosis. A PNS event was considered 'concomitant' to SLE if it was diagnosed within three months of SLE onset. For peripheral neuropathy, data included features of peripheral neurological events, and the electrophysiological test results when available. Pure compression neuropathy (e.g. of the median nerve in the carpal tunnel) was not included in the analysis, as it is not attributable to SLE.
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The final neurological diagnosis was also extracted by reviewing the patients' charts. We examined all seven peripheral manifestations listed in 1999 ACR nomenclature and case definition, 2 retrospectively attributing them according to the attribution rules as explained elsewhere; 12, 13 we considered (i) the temporal relationship between NP events and the diagnosis of SLE; (ii) confounding factors (i.e. alternative causes or non-SLE contributing factors derived from the ACR case definitions for 19 NP syndromes); (iii) minor or common NP events identified as described by Ainiala et al.; 14 and (iv) favouring factors (i.e. clinical and non-clinical variables which support the attribution to SLE). Besides cases defined by the 1999 ACR nomenclature, patients with small-fibre neuropathy diagnosed by 'skin punch' biopsy were also included in the study.
The outcome of PNS manifestations was classified on a physician's 7-point Likert scale (1 ¼ patient demise, 2 ¼ much worse, 3 ¼ worse, 4 ¼ no change, 5 ¼ improved, 6 ¼ much improved, 7 ¼ resolved). 15 The outcome response for all PNS events was retrospectively estimated from clinical chart review after one year of follow-up and scored as 'much improved or resolved' (score !5); 'no change' (score ¼ 4) or 'worse' (score 3).
Associated factors
Disease activity was routinely assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K), 16 measured at the onset time of the NP event. Damage was calculated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI). 17 We also checked a large panel of factors and/or comorbidities in all patients. Risk factors were categorized as generic (not strictly SLE-related) or specific (SLE-related), and each of them was defined as reported elsewhere. 18, 19 Generic factors included: hypertension, diabetes, dyslipidemia, smoking habit (>10 cigarettes/day); specific factors were anti-phospholipid antibodies (aPLs) including anti-cardiolipin (aCLs) and antiBeta2-glycoprotein I (aB2GP1) antibodies (both IgG and IgM isotypes), lupus anticoagulant (LA), anti-Ro/SSA and anti-Sm antibodies, rheumatoid factor, cryoglobulins, anti-phospholipid syndrome (APS), secondary Sjo¨gren's syndrome (defined according to the criteria proposed by the American European Consensus Group 20 ), Raynaud's phenomenon and livedo reticularis, registered in clinical charts and ascertained either from history or direct medical observation. Immunological parameters were: total serum gammaglobulins (g/l); complement fractions C3 and C4 (g/l), detected by nephelometry (hypocomplementaemia was defined as C3 < 0.8 and C4 < 0.11 g/l); anti-nuclear antibodies (ANAs), tested by indirect immunofluorescence (IIF) using Hep2 cell substrate (positivity was defined as a titre !1: 160); and rheumatoid factor, analyzed using standard ELISA methods. For the identification of cryoglobulins, serum was prepared after warm centrifugation at 37 C and observed at 4 C for formation of cryoprecipitate. 21 Anti-extractable nuclear antigen (ENA) antibodies and anti-dsDNA were analyzed by each centre using routine validated assays.
Treatment and medications recorded (ongoing at the time of the event and started/modified after new PNS event) were: corticosteroids (CS), hydroxychloroquine, immunosuppressive drugs (cyclophosphamide (CYC), azathioprine (AZA), mycophenolate mofetil (MMF), cyclosporine A (CYA), methotrexate (MTX)), rituximab, intravenous immunoglobulins (IVIG), plasma exchange (PEX), neuroleptics, neurotrophics and/or other relevant treatments (e.g. anti-platelet therapy or anticoagulants). In the control group (no PNS involvement), we recorded ongoing treatment at the time of study inclusion.
Statistical analysis
Frequency calculations and descriptive statistics were used in the assessment of patient characteristics. Either the chi-square test or Fisher's exact test, as appropriate, was used for group comparisons involving binary data. For continuous variables, a two-tailed Student's t-test or a nonparametric Mann-Whitney U test was used to perform comparisons between groups. The results were considered significant at p < 0.05. Data processing and statistical analyses were performed using MedCalc for Windows, version 9.5.0.0 (MedCalc Software, Mariakerke, Belgium).
Results
Demographic and clinical data
A total of 1224 patients -804 from Ferrara and 420 from Cagliari -attended our lupus clinics during the indicated timeframe. Overall, 58 out of 804 patients (7.2%, 95% confidence interval (95%CI) 0.06-0.09) and 27 out of 420 patients (6.4%, 95%CI 0.044-0.092), respectively, had experienced at least one PNS event for a total of 97 PNS events in 85 patients (6.9%, 95%CI 0.06-0.08). Of these, 61 patients (4.9%, 95%CI 0.04-0.06) had experienced a PNS manifestation which we attributed to SLE. Demographic, clinical and laboratory data are reported in Table 1 . In the SLE-PNS group, 85.9% of patients were female, their mean age at SLE onset was 45.9 years (standard deviation, SD 14.8), and their mean (SD) disease duration at the time of the event was 5.8 years (9.2). In two cases, the event preceded the diagnosis of SLE, and in 26 patients, PNS involvement appeared at the onset of the disease, while in the remaining 57 patients, PNS involvement appeared more than three months after the diagnosis of SLE. A total of 40 patients had both CNS and PNS events. In 13 cases, the CNS event was concomitant, in eight subsequent, and in 26 cases it occurred before the peripheral one.
Peripheral nervous system events
The most common PNS event observed was peripheral polyneuropathy (42 events, 43.3% of 97), with a predominance of the sensory-motor form, which accounted for 25% of events, while the sensory variant was recorded in 13%. Thirty events (30.9%) were diagnosed as cranial neuropathy, single in 12 (12.4%) and multiple in eight (8.2%). Small-fibre neuropathy accounted for four events (4.1%), myasthenia gravis for three (3.1 %), and plexopathy and autonomic neuropathy accounted for one event each (1%) ( Table 2 ). In our cohort, there were no cases of GBS or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Using the attribution algorithm for NP events, applied as previously reported, 13, 22 66 (68%) out of 97 PNS events in 61 patients reached the defined cut-off point for proper attribution to SLE and can therefore be considered manifestations of the disease (Table 2 ). Mononeuritis multiplex (85%, 17/20 events) and cranial neuropathies (93.3 %, 28/30 events) were more likely to be SLErelated.
Comparison of patients with and without PNS events
SLE patients with PNS involvement were matched (by sex and SLE duration) to 243 control SLE patients without central or peripheral manifestations (1:3 ratio). In both groups, most patients were female, and all were Caucasian. The age at SLE diagnosis was significantly higher in patients with PNS involvement, and they were more likely to have higher SLEDAI-2K and SDI scores (Table 1) . There was no significant difference in lupus serology between the two groups. However, among the clinical characteristics, an association was observed with concomitant Sjo¨gren's syndrome in cases with PNS involvement (p ¼ 0.005), while malar rash and photosensitivity were more common in controls. A subgroup analysis, including only the SLE-related PNS manifestations and their controls, yielded similar results concerning significantly older age, higher SDI and SLEDAI-2K in cases with PNS involvement as compared to SLE controls.
Generic and specific risk factors
Among generic risk factors, smoking habit (p ¼ 0.04), diabetes (p < 0.0000) and hypertension (p < 0.0000) were more often reported in patients with peripheral involvement, while livedo reticularis was the only specific risk factor correlated to PNSLE (p ¼ 0.006). No patient in the SLE-PNS group was taking contraceptives, while these were recorded for 10.5% of the SLE control group. In the subgroup of patients with PNS-related events, concomitant hypertension (p ¼ 0.002) and livedo reticularis (p ¼ 0.02) were significantly more common than in the SLE control group.
Therapeutic approach and outcome
The therapeutic approach, recorded at the time of PNS event onset, most frequently relied on pulsed CS or moderate-to-high dose background CS and enhanced immunosuppression for attributed events. Neurotrophic and neuroleptic agents were generally adopted in polyneuropathies. Table 3 shows a detailed breakdown of therapeutic approaches, and Table 4 shows the short-term outcomes of the most frequent PNS events in our cohort. Of the 85 patients whose short-term outcome was assessed one year after the onset of the PNS event, there was a resolution or significant improvement in 56 cases (65.9%). Overall, improvements were seen in 14/22 (63.6%) cases of polyneuropathy attributed to SLE and 11/18 (61.6%) cases of polyneuropathy not attributed to SLE, while only 4/22 (18.2%) of attributed and 2/18 (11.1) not-attributed polyneuropathies worsened. All the not-attributed mononeuropathies and cranial neuropathies improved, and only 1/14 (7.1%) attributed mononeuropathies and 1/26 (3.8%) attributed cranial neuropathies worsened. Myasthenia and plexopathy showed an improvement during follow-up, whereas autonomic neuropathy did not change.
Discussion
The ultimate aim of our study was to define the overall prevalence of PNS involvement in SLE and to profile patients with SLE complicated by PNS manifestation(s). The prevalence of PNS manifestations in our SLE sample is similar to that reported by Oomatia et al. 7 and Hanly et al. 23 -in the SLICC cohort, out of 843 NP events, 58 (6.9%) involved PNS -but slightly lower than the findings of Florica et al. 24 and Toledano et al. 25 Indeed, Oomatia et al., 7 reported a prevalence of peripheral neurological involvement in 6% (123/2097) of patients, very similar to the 6.4 to 6.8% we found. However, it is worth noting that in that study, 7 in addition to meeting ACR criteria for NPSLE, patients had to adhere to the definitions of peripheral neuropathy provided by the Task Force of the American Academy of Neurology and the American Academy of Physical Medicine and Rehabilitation. Furthermore, those authors excluded patients with cranial neuropathies and paid close attention to small-fibre involvement, which was not included in the original ACR nomenclature but was seen more frequently than other symptoms, being demonstrated by skin biopsy in 17.1% of patients (14 out of 82). Florica et al., 24 on the other hand, reported polyneuropathy in 207/1533 patients (14%), and in their cohort, another manifestation not listed in the ACR case definition, CIDP, was included and In our study, the prevalence of individual PNS events was very similar to the average prevalence observed in the literature meta-analysis carried out by Unterman et al., confirming their finding that peripheral polyneuropathy is the most common manifestation, followed by cranial nerve neuropathy. 26 We also confirm that GBS and plexopathy are extremely rare in SLE, suggesting, as already hypothesized, that they may be a manifestation of a distinct and coincidental neurological syndrome. 7 Autonomic neuropathy was another very rare manifestation in our sample, although the retrospective nature of our study and the multifaceted character of this disease might have led to an underestimation of its effective prevalence.
Like prior studies, our data highlight the importance of a careful diagnostic workup of SLE-related PNS manifestations. Regarding attribution, 71.7% of our patients experienced at least one PNS manifestation deemed as related to SLE (68%, 61/85 of all the events). Similarly, Oomatia et al. reported 67% of patients (82/123) as having PNSLE, while 33.3% had PNS events due to other non-SLE aetiologies (e.g. infectious or metabolic). 7 Likewise, Florica et al. 24 reported that 39.6% of all PNS events registered were judged as not-SLE related (major causes were entrapment neuropathies, iatrogenic aetiologies, hypothyroidism and diabetes mellitus; other causes were ethanol abuse, paraproteinemia, uraemia, viral hepatitis).
Analyzing the type of the event, multiplex mononeuritis was more likely to be SLE-related. This observation is supported by Florica et al. 24 and is in line with the new classification criteria for SLE that include this event, deeming it very specific. In our series, another very specific event was cranial neuropathy; this was attributed to SLE in more than 93% of the patients in which it occurred, making it very indicative of primary NPSLE.
A comparison of the clinical and demographic data pertaining to patients with and without PNS involvement revealed that an older age at disease onset, greater disease activity and higher SDI score are traits associated with PNS manifestations of SLE; this is in line with data from several studies that have solely focused on the description of peripheral involvement in SLE. 6, 7, 24, 25 Also consistent with previous findings, signs of PNS involvement in our SLE sample seemed to characterize patients with different comorbidities or risk factors (Table 5) .
We investigated the association of PNS involvement in SLE with general and specific risk factors, an aspect not covered by previous studies, even though Oomatia et al. did report an association with opportunistic infections and osteoporotic fractures. 7 In our cohort, we found an association with secondary Sjo¨gren's syndrome, smoking habit and diabetes during PNS events, but none of these factors showed a strong association with SLE attribution, indicating them to be possible confounders. In fact, of all the factors investigated, only hypertension and livedo reticularis were confirmed as being associated with SLE-related PNS involvement.
However, the role of cardiovascular risk factors, in particular diabetes and smoking, in the occurrence of PNS events may be ambiguous and therefore warrants further discussion. Indeed, they may be considered not only confounding factors but also could make SLE patients more prone to PNS subclinical suffering. This hypothesis is supported by relevant literature data which point towards increased prevalence of neuropathy and accelerated micro-angiopathic complications of type II diabetes in patients with metabolic syndrome, smoking habits, etc., thereby suggesting a synergistic effect. 27, 28 That being said, as our study was retrospective, we are unable to present data regarding the presence of predisposing conditions, e.g. prediabetes. How these factors interact with SLE-related pathogenic mechanisms is currently unknown. However, it is worth noting that neither diabetes nor smoking habits remained significantly associated with PNS events after application of the attribution algorithm.
As mentioned above, none of the patients with PNS involvement was taking contraceptives; this aspect may be partly justified by the more advanced median age of this group and therefore by a reduced need for contraceptive measures. Another possibility could be that patients with PNS involvement shared higher cardiovascular risk (inferred by higher intake of antiplatelet/anticoagulant agents and a higher prevalence of hypertension in both attributed and not-attributed groups), thereby resulting in less frequent prescription of contraceptives.
Indeed, despite significant advances in understanding their pathogenesis, the causes of the heterogeneity of acute and chronic immune neuropathies remain largely unresolved. Nevertheless, small vessel vasculitis may play a role, as supported by its association with several conditions potentially linked to alterations in Peripheral nervous system involvement in SLE A Bortoluzzi et al.
microcirculation (older age, smoking habits, hypertension). In this context, the onset of an autoimmune disease such as SLE could act as a second strike, inducing symptomatic peripheral manifestations. On a related note, we are unable to rule out a role for concomitant APS in the pathogenesis of PNS manifestations, despite not having found an association in our study.
We also found no significant association between lupus serology and PNS manifestations; of note, our data showed no association with increased cryoglobulins -a parameter recently implicated in the course of multiple mononeuropathy in SLE, with a reported prevalence of up to 55% of cases. 29 The role of autoantibodies in PNS involvement in SLE is still controversial, as contrasting data are reported in the literature. Further studies are needed to clear up this issue.
In our retrospective cohort, patients were treated in accordance with EULAR recommendations for the management of NPSLE. 30 Cranial neuropathies were managed via CS and immunosuppressants, while neurotrophic and neuroleptic agents were also employed in polyneuropathies, reserving PEX and IVIG for severe cases. The only controlled clinical trial designed for NPSLE patients 31 showed that the efficacy of intravenous CYC treatment was greater with respect to pulses of CS in severe peripheral neuropathies, but only seven cases of polyneuropathy were involved in the trial. In our cohort, most of the attributed events were treated using CS; among the immunosuppressants used for severe polyneuropathies, MMF and CYC shared similar prescription rates. In our cases, we confirmed the recommended treatment for (single or multiple) mononeuritis, namely CS, immunosuppressants and PEX/IVIG -a treatment strategy aimed at lessening inflammation around the epineurium. 32 Regarding short-term outcomes, our results indicate quite a good prognosis for PNSLE. We found improvement in approximately 60% of polyneuropathies, while, among SLE-attributed cases, only 18% worsened and the same percentage remained stable. Overall, only one out of 14 mononeuropathies and one out of 26 cranial neuropathies got worse. The explanation for this favourable prognosis may lie in the presumptive inflammatory background behind these neurological events, which could have induced a more aggressive treatment approach.
As mentioned, one limitation of our study is its retrospective design. Indeed, this could have hampered the correct recognition of some PNS events, such as small-fibre neuropathy and autonomic neuropathy. Prospective studies could better define the effective prevalence of these complications in the future. Meanwhile, however, it is advisable to implement quick and easy tests for autonomic neuropathy (e.g. 10 minute in-office stand test for postural orthostatic tachycardia syndrome and orthostatic intolerance or tilt table SELENA-SLEDAI applied.
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testing for neurocardiogenic syncope) and specific diagnostic investigations for small-fibre neuropathy (e.g. quantitative sensory testing (QST), skin biopsy, etc.) in routine clinical settings in order to perform a complete diagnostic workup in all SLE patients complaining of sensory/autonomic symptoms, however mild. Some data, especially on rheumatoid factors and cryoglobulins, were only available for some of our patients, which made it difficult to obtain conclusive evidence on their effective association with PNS manifestations in SLE. Moreover, analysis of the evolution of PNS events was not possible in all patients, and we were unable to assess their impact on the quality of life perceived by the patient. Finally, we are only able to provide short-term follow-up data, which prevents us providing comprehensive information as to possible relapses. Despite this, the use of stringent and validated criteria to determine whether peripheral manifestations were attributable to SLE should be considered a strength of our study, which provides a significant contribution to furthering knowledge of primary NPSLE, especially regarding PNS events.
Conclusion
Further to a recent review by our group, in which we examined epidemiological data and new pathogenic and clinical evidence on PNS involvement in SLE, 33 here we set out to characterize clinical and demographic features related to PNSLE, distinguishing between events deemed attributable or not attributable to SLE. This investigation showed that older age at SLE onset, greater disease activity and higher damage scores were factors related to PNS events, in line with previous reports. We also substantiate the role of these demographic factors and disease-related outcomes, demonstrating a correlation with PNS events directly attributed to SLE. In addition, from our data, livedo reticularis and hypertension emerge as additional potential risk factors in PNS; in the case of hypertension, this suggests that there may be an opportunity to identify novel preventative strategies aimed at unexpected targets (such as PNS events). Further studies will help us to better define to what extent the proper recognition of NPSLE, ensured by applying the attribution algorithm, could affect the appropriateness of treatment. Meanwhile, the recommendation that emerges from current data is that careful and thorough clinical, instrumental and global workup of the SLE patient complaining of PNS symptoms is essential in order to better and more promptly recognize, attribute and manage such a neglected manifestation of the disease.
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